Escitalopram + Esketamine + Venlafaxine + Duloxetine + SERTRALINE for depressive disorder, treatment-resistant

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 10 Jul 2015: Trial registered, NCT02493868
  2. 14 Jul 2015: Trial registered, NCT02497287
  3. 30 Sep 2015: Trial started, NCT02497287
  4. 1 Oct 2015: Trial started, NCT02493868

The trials

NCT02493868: A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

State
Completed
Phase
Phase 3
People
719 taking part
Started
1 Oct 2015
Primary completion
15 Feb 2018
Arms
Intranasal Esketamine plus oral antidepressant
Results
Posted on the registry
  1. 10 Jul 2015: Trial registered
  2. 1 Oct 2015: Trial started
  3. 16 Feb 2018: Trial completed
  4. 21 May 2019: Trial results posted

NCT02497287: A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

State
Completed
Phase
Phase 3
People
802 taking part
Started
30 Sep 2015
Primary completion
28 Oct 2017
Arms
Intranasal Esketamine plus oral antidepressant
Results
Posted on the registry
  1. 14 Jul 2015: Trial registered
  2. 30 Sep 2015: Trial started
  3. 28 Oct 2017: Trial completed
  4. 29 Apr 2019: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.